Navigation Links
PTC Therapeutics Announces Data Showing Six-Minute Walk Test Consistently Measures Ambulatory Function in Patients With Duchenne Muscular Dystrophy
Date:9/30/2008

- Findings Suggest Clinically Meaningful Primary Endpoint for Clinical Trials; Data Presented at the 13th International World Muscle Society Congress -

SOUTH PLAINFIELD, N.J., Sept. 30 /PRNewswire/ -- PTC Therapeutics, Inc. (PTC) today announced promising findings in patients with Duchenne/Becker Muscular Dystrophy (DMD/BMD) at the 13th International World Muscle Society (WMS) Congress. Results from an observational study assessing the utility of the 6-minute walk test (6MWT) as a primary outcome measure in trials of treatment for DMD/BMD showed that the 6MWT clearly differentiates boys with DMD from healthy boys, especially when adjusted for age. The findings also demonstrate that the 6MWT provides a reliable assessment of ambulatory function in boys as young as five years of age, offering a practical and clinically meaningful outcome measure for use in DMD/BMD registration-directed clinical trials. Results from the study were presented today by Craig McDonald, M.D., principal investigator and director of the Rehabilitation Research and Training Center in Neuromuscular Diseases, University of California Davis.

(Logo: http://www.newscom.com/cgi-bin/prnh/20010919/PTCLOGO )

There has been a strong interest in establishing clinically meaningful outcomes measures to advance the development of new treatments for DMD/BMD. The 6MWT is an accepted and standardized measure of ambulatory capacity that was developed to provide an integrated assessment of cardiac, respiratory, circulatory and muscular capacity. Until this study, it had been unclear whether boys with DMD would have the stamina and mental focus to successfully finish the test without injury. This study demonstrated that ambulatory boys with DMD as young as five years old can complete the 6MWT safely and reliably with minimal interruption from falls. The study found that the muscular deficits that are chara
'/>"/>

SOURCE PTC Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Data from In Vivo Disease Models on Taligen Therapeutics Pipeline Candidates to be Presented at the XXII International Complement Workshop
2. Data Confirm Synvista Therapeutics Haptoglobin Diagnostic Test Kit Success in Rapidly Determining Cardiovascular Risk in Patients with Diabetes
3. Logical Therapeutics Inc. Commences Double-Blind, Randomized Study of Their Lead Program, LT-NS001
4. Agile Therapeutics Achieves Phase 2 Study Endpoints in Key Clinical Trials with New, Innovative Low-Dose Contraceptive Patch
5. Tobira Therapeutics Inc. Receives US Patent for TBR-652
6. MabVax Therapeutics Closes Two Licensing Agreements With Sloan-Kettering Institute for Cancer Research
7. Cell Therapeutics Announces that the European Organization for Research and Treatment of Cancer Completes Enrollment in Phase II Clinical Trial of Brostallicin as First Line Therapy for Advanced or Metastatic Soft Tissue Sarcoma
8. Amicus Therapeutics Announces Second Quarter 2008 Financial Results
9. Cara Therapeutics Announces Successful Completion of Phase I Clinical Trial of Novel Analgesic, CR845
10. Amicus Therapeutics Announces Successful Completion of End of Phase 2 Meeting With FDA for Amigal in Fabry Disease
11. Nile Therapeutics Announces Dosing in Second Phase Ib Study of CD-NP in Heart Failure Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... -- Tandem Diabetes Care®, Inc. (NASDAQ: TNDM ), ... Pump, today reported its financial results for the quarter ended ... quarter of 2014 to the same period of 2013: ... million , t:slim Pump shipments grew 64 percent to ... months ended June 30, 2014 to the same period of ...
(Date:7/31/2014)... , July 31, 2014  Cepheid (NASDAQ: CPHD ... the following conferences, and invited investors to participate via webcast. ... New York, NY Wednesday, August 13, ... Health Care Conference, New York, NY ... Accessing Live Webcasts To access the live webcasts ...
(Date:7/31/2014)... , July 31, 2014   Auxilium Pharmaceuticals , ... specialty biopharmaceutical company, today announced that the Company will ... Thursday, August 7, 2014 before the opening of the ... conference call that day at 8:30 a.m. ET to ... 2014. The presentation slides to be used during the ...
Breaking Medicine Technology:Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 2Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 3Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 4Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 5Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 6Cepheid to Webcast Upcoming Financial Presentations 2Auxilium Pharmaceuticals, Inc. To Announce Second Quarter 2014 Results On August 7, 2014 2Auxilium Pharmaceuticals, Inc. To Announce Second Quarter 2014 Results On August 7, 2014 3
... III Study Provides Further Evidence of,the Significant ... Treatment,of Rheumatoid Arthritis, BASEL, Switzerland, June 6, ... multinational phase III Actemra,(tocilizumab) study, successfully reached ... proportion of patients treated with Actemra,in combination ...
... Topical Therapy Reduces TNF-alpha Production Through Inhibition,of ... 2007 /PRNewswire/ -- Anacor,Pharmaceuticals, a privately held ... placebo-controlled Phase 1 trial of,AN2728, a first-in-class ... psoriasis. The trial showed AN2728 to be,well-tolerated, ...
Cached Medicine Technology:New Data Confirms Significant Improvement of Disease Signs and,Symptoms in Patients with Rheumatoid Arthritis 2New Data Confirms Significant Improvement of Disease Signs and,Symptoms in Patients with Rheumatoid Arthritis 3New Data Confirms Significant Improvement of Disease Signs and,Symptoms in Patients with Rheumatoid Arthritis 4Anacor Clinical Study of AN2728, a Novel Anti-Inflammatory,Compound, Shows Efficacy in Psoriasis 2
(Date:7/31/2014)... (PRWEB) July 31, 2014 Etymotic ... announced a new sponsorship of the DrumLine Battle® ... are Etymotic’s hearing protection products ETY•Plugs® and Music•PRO® ... against the harmful effects of high-level sound. Etymotic ... sponsorship at the Drum Corps International Championships on ...
(Date:7/31/2014)... black women put concerns about their hair above their ... the U.S. Centers for Disease Control and Prevention that ... States are overweight or obese. Yet some of them ... their hair restyled or restraightened, the University of Colorado ... also noted a shift toward more "low-maintenance" hairstyles, which ...
(Date:7/31/2014)... (PRWEB) July 31, 2014 Rich Dad® ... charity yard sale to benefit Habitat for Humanity. The yard ... was raised with 100% of the proceeds donated to Habitat ... items not sold at the event were donated to the ... Road, North Fort Myers, Florida 33903. , Of the ...
(Date:7/31/2014)... aimed to diagnose pediatric patients with suspected appendicitis ... without affecting diagnostic accuracy, Mayo Clinic Children,s Center ... in the journal Surgery . , Acute ... abdominal pain in children. Appendicitis occurs when the ... scans are often used to diagnose acute appendicitis ...
(Date:7/31/2014)... (PRWEB) July 31, 2014 Insight Accelerator ... a Series A round of investment for $4.6 million ... device for collecting vital signs. The company joined ... technology to fruition with the help of Insight development ... our reason for launching the Accelerator,” says Steve McPhilliamy, ...
Breaking Medicine News(10 mins):Health News:Etymotic Research Becomes The Official Hearing Protection Sponsor Of DrumLine Battle 2Health News:Hairdo Trumps Exercise for Many Black Women, Study Finds 2Health News:Rich Dad Education Charity Yard Sale to Benefit Habitat for Humanity of Lee and Hendry Counties a Success 2Health News:Insight Accelerator Labs Advances Member Toward Commercialization 2Health News:Insight Accelerator Labs Advances Member Toward Commercialization 3
... rats finds that even one injection leads to dependent ... naturally occurring protein plays a role in the disrupted ... with drug and alcohol dependence, says a new study. ... changes in association with drug abuse, it could potentially ...
... May 28 (HealthDay News) --Should it worry you that there ... , Not especially, when you consider that there are 44 ... , This information comes to you from scientists at the ... same techniques that enabled them to map the human genetic ...
... Controlling Weight before PregnancyWHITE PLAINS, N.Y., May 28 ... right amount during pregnancy is critical to giving a ... Dimes said today in response to new guidelines from ... issued new guidelines for the amount of weight a ...
... Logistics (NGL), a premier provider of mission critical transportation, service/spare parts ... network of forward stocking locations (FSL,s). , ... Broomfield, ... provider of mission critical transportation, service/spare parts logistics , and ...
... Perot Systems, RCS advantages of increased cash flows and ... providersPLANO, Texas, May 28 Amerinet, a leading national ... PER ) ( www.perotsystems.com ) ... Systems revenue cycle solutions available to Amerinet,s acute and ...
... Patent Covers High-throughput, Anchorage-independent Assay for Screening Compounds ... Falcon Genomics, Inc. announced today that it ... covering the Company,s Cancer BioChip System (CBCS) for ... in a high-throughput in vitro setting ...
Cached Medicine News:Health News:Study Finds Multitude of Bacteria on Human Skin 2Health News:Study Finds Multitude of Bacteria on Human Skin 3Health News:New Guidelines to Fight Obesity in Pregnancy Issued 2Health News:New Guidelines to Fight Obesity in Pregnancy Issued 3Health News:NGL Expands Global Network to Service Parts Logistics Customers 2Health News:NGL Expands Global Network to Service Parts Logistics Customers 3Health News:Perot Systems to Supply Revenue Cycle Solutions to Amerinet Members Nationwide 2Health News:Perot Systems to Supply Revenue Cycle Solutions to Amerinet Members Nationwide 3Health News:Falcon Genomics Awarded Patent for Innovative Cancer Test 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: